44
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of brigatinib, as compared with crizotinib, in patients with advanced ALK-positive NSCLC who have not previously received an ALK inhibitor is unclear.

          Related collections

          Author and article information

          Journal
          New England Journal of Medicine
          N Engl J Med
          New England Journal of Medicine (NEJM/MMS)
          0028-4793
          1533-4406
          September 25 2018
          September 25 2018
          Affiliations
          [1 ]From the University of Colorado Cancer Center, Aurora (D.R.C.); Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine (H.R.K.), Samsung Medical Center (M.-J.A.), and Seoul National University Hospital (D.-W.K.), Seoul, National Cancer Center, Goyang (J.-Y.H.), Seoul National University Bundang Hospital, Seongnam (J.-S.L.), and Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.) —...
          Article
          10.1056/NEJMoa1810171
          30280657
          90782fe7-9f15-4b8f-81ba-732be942409b
          © 2018

          http://www.nejmgroup.org/legal/terms-of-use.htm

          History

          Comments

          Comment on this article